ABNOM
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
References
Laser Q-switched Nd:YAG tête zanîn ku bi bandor nevus of Ota û şertên mîna wan derman dike. Me lêkolînek kir da ku em bibînin ka lazerek high-fluence 1064 nm Q-switched Nd:YAG çiqas baş li ser lekeyên mongolî yên li deverên neasayî dixebitî, bêyî ku bibe sedema ronîbûna çerm. Me 61 nexweşên bi van deqan lêkolîn kir, bi tevahî 70 birîn lêkolîn kirin. Nîvê birînan bi lazerê hatin dermankirin, yên din jî ji bo berhevdanê bê derman hatin hiştin. Me encam bi pîvanek û amûrek bi navê Mexameter® nirxand da ku asta melanin bipîve. Nexweş bi navînî 14 mehan di koma dermankirinê de û 18 mehan di koma çavdêriyê de hatin şopandin. Di dawiya lêkolînê de, me cûdahiyên girîng di pîvanên pîvanê û astên melanîn de di navbera komên dermankirî û nehatine derman kirin de dît, digel ku koma ku bi lazerê hatî derman kirin encamên çêtir nîşan dide. Lazera high-fluence Q-switched Nd:YAG , bêyî ku bibe sedema ronahiya çerm, ji bo dermankirina van deqên mongolî yên bêhempa bi bandor û ewledar derket.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Me bandor û ewlehiya karanîna tedawiyek lazerek taybetî ya ji bo ABNOM lêkolîn kir, û li ser kîjan faktoran dikarin bandor bikin ka ew çiqas baş dixebite. Me li 110 nexweşên ku ABNOM hebûn û di navbera du û neh dermankirinên lazerê de nihêrîn. Me dît ku dermankirin her ku dirêjtir were kirin çêtir dixebitî, lê di nexweşên pîr de ne bi vî rengî. Di heman demê de ew li nexweşên bi çermê sivik (cure III) û deverên piçûktir ên bandorkirî (kêmtir ji 10 cm2) çêtir xebitî. Hebûna melasma bi ABNOM re dermankirin kêmtir bandorker kir. Reng an hejmara deverên bandorkirî cûdahî xuya nedikir. Nêzîkî 10% ji nexweşan piştî dermankirinê lekeyên tarî peyda bûn. Tedawiya piralî ya destpêkê encamên baş da. Nexweşên pîr ên ku çermê wan tarîtir û deqên tarîtir in, piştî dermankirinê îhtîmal e ku lekeyên tarîtir bibin. Ji bo nexweşên ABNOM û melasmayê, çêtir e ku meriv lazerek bi enerjiya kêmtir bikar bînin da ku melasma xirabtir nebe.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Demankirinî
Nûnerên spîker kêm kêm alîkariyê dikin. Berevajî melasmayê, ABNOM dikare bi tedawiya lazerê were baştir kirin û bê dûbare were rakirin. Ji bo dermankirina ABNOM-ê dermankirina lazer dikare 10 û 20 carî were kirin.
#QS1064 laser